Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies

抗体作为药物：工程抗体治疗应用的新视野

• 批准号: 9761645
• 负责人: Thale Cross Jarvis
• 金额: $ 0.5万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-02-20 至 2020-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9761645
• 关键词: Academia; Antibodies; Antibody Therapy; Antibody-drug conjugates; Area; Autoimmune Diseases; Bispecific Antibodies; Career Choice; Collaborations; Colorado; Communicable Diseases; Data; Development; Disease; Engineering; Fertilization; Fostering; Future; Goals; Health; Human; Immunoglobulin G; Immunotherapeutic agent; Industry; Learning; Malignant Neoplasms; Mentors; Outcome; Patients; Pharmaceutical Preparations; Play; Production; Recombinant Antibody; Research; Research Personnel; Scientist; State-of-the-Art Reviews; Technology; Therapeutic; Therapeutic Uses; Therapeutic antibodies; antibody engineering; career; clinical development; clinical practice; design; improved; insight; meetings; new technology; novel; posters; preclinical development; scaffold; symposium; therapeutic development

ABSTRACT Support is requested for a Keystone Symposia conference entitled Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies, organized by Drs. Christian Klein, Mark S. Cragg and Germaine Fuh. The conference will be held in Breckenridge, Colorado from April 7-11, 2019. Over the last twenty years, recombinant antibodies have been established into clinical practice for the treatment of diseases ranging from cancer, to autoimmune and infectious diseases. While the first approved antibodies were native IgG antibodies, in recent years the field has rapidly advanced and therapeutic antibodies in preclinical and clinical development now include many non-canonical formats including Fc- engineered antibodies, antibody drug conjugates, bispecific antibodies and antibody-like scaffolds. This Keystone Symposia conference aims to bring together experts in antibody therapeutics, engineering and mechanisms of action from industry and academia to discuss and review the state-of-the-art in the field and discuss their future potential. The conference will foster cross-fertilization between different engineering technologies and scientists from different therapeutic areas. This conference can also help to initiate collaboration on the development of state-of-the-art antibody therapies with the aim to improve therapeutic options for patients. For trainees and early career researchers, this conference provides an opportunity to gain insight into various aspects of therapeutic antibodies and to discuss their projects and ideas face-to-face with experts in the field. A unique component to this conference that distinguishes it from other more commercial meetings in the field, is that this conference will include presentation and discussion of novel/unpublished data.

抽象的 请求支持题为“抗体作为药物：新视野”的 Keystone 研讨会 工程抗体的治疗用途，由博士组织。克里斯蒂安·克莱因、马克·S·克拉格和杰曼 呃。会议将于2019年4月7日至11日在科罗拉多州布雷肯里奇举行。 在过去的二十年里，重组抗体已进入临床实践 治疗从癌症到自身免疫性疾病和传染病的疾病。虽然第一个获批的 抗体是天然的 IgG 抗体，近年来该领域迅速发展并具有治疗作用 临床前和临床开发中的抗体现在包括许多非规范格式，包括 Fc- 工程抗体、抗体药物偶联物、双特异性抗体和抗体样支架。这 Keystone Symposia 会议旨在汇聚抗体治疗、工程和技术领域的专家 工业界和学术界讨论和审查该领域最新技术的行动机制 讨论他们未来的潜力。会议将促进不同工程之间的交叉融合 来自不同治疗领域的技术和科学家。这次会议还可以帮助发起 合作开发最先进的抗体疗法，旨在提高治疗效果 患者的选择。对于学员和早期职业研究人员来说，本次会议提供了获得知识的机会 深入了解治疗性抗体的各个方面，并与他们面对面讨论他们的项目和想法 该领域的专家。这次会议的一个独特组成部分使其与其他更商业化的会议区分开来 该领域的会议的一个特点是，本次会议将包括新颖/未发表数据的介绍和讨论。